Estimated  ||| S:0 E:10 ||| JJ
mortality  ||| S:10 E:20 ||| NN
of  ||| S:20 E:23 ||| IN
adult  ||| S:23 E:29 ||| JJ
HIV-infected  ||| S:29 E:42 ||| JJ
patients  ||| S:42 E:51 ||| NNS
starting  ||| S:51 E:60 ||| VBG
treatment  ||| S:60 E:70 ||| NN
with  ||| S:70 E:75 ||| IN
combination  ||| S:75 E:87 ||| NN
antiretroviral  ||| S:87 E:102 ||| NN
therapy  ||| S:102 E:110 ||| NN
To  ||| S:110 E:113 ||| TO
provide  ||| S:113 E:121 ||| VB
estimates  ||| S:121 E:131 ||| NNS
of  ||| S:131 E:134 ||| IN
mortality  ||| S:134 E:144 ||| NN
among  ||| S:144 E:150 ||| IN
HIV-infected  ||| S:150 E:163 ||| JJ
patients  ||| S:163 E:172 ||| NNS
starting  ||| S:172 E:181 ||| VBG
combination  ||| S:181 E:193 ||| NN
antiretroviral  ||| S:193 E:208 ||| NN
therapy ||| S:208 E:215 ||| NN
.  ||| S:215 E:217 ||| .
We  ||| S:217 E:220 ||| PRP
report  ||| S:220 E:227 ||| VBP
on  ||| S:227 E:230 ||| IN
the  ||| S:230 E:234 ||| DT
death  ||| S:234 E:240 ||| NN
rates  ||| S:240 E:246 ||| NNS
from  ||| S:246 E:251 ||| IN
122  ||| S:251 E:255 ||| CD
925  ||| S:255 E:259 ||| CD
adult  ||| S:259 E:265 ||| NN
HIV-infected  ||| S:265 E:278 ||| JJ
patients  ||| S:278 E:287 ||| NNS
aged  ||| S:287 E:292 ||| VBN
15  ||| S:292 E:295 ||| CD
years  ||| S:295 E:301 ||| NNS
or  ||| S:301 E:304 ||| CC
older  ||| S:304 E:310 ||| JJR
from  ||| S:310 E:315 ||| IN
East ||| S:315 E:319 ||| NNP
,  ||| S:319 E:321 ||| ,
Southern  ||| S:321 E:330 ||| NNP
and  ||| S:330 E:334 ||| CC
West  ||| S:334 E:339 ||| NNP
Africa ||| S:339 E:345 ||| NNP
,  ||| S:345 E:347 ||| ,
Asia  ||| S:347 E:352 ||| NNP
Pacific  ||| S:352 E:360 ||| NNP
and  ||| S:360 E:364 ||| CC
Latin  ||| S:364 E:370 ||| NNP
America ||| S:370 E:377 ||| NNP
.  ||| S:377 E:379 ||| .
We  ||| S:379 E:382 ||| PRP
use  ||| S:382 E:386 ||| VBP
two  ||| S:386 E:390 ||| CD
methods  ||| S:390 E:398 ||| NNS
to  ||| S:398 E:401 ||| TO
adjust  ||| S:401 E:408 ||| VB
for  ||| S:408 E:412 ||| IN
biases  ||| S:412 E:419 ||| NNS
in  ||| S:419 E:422 ||| IN
mortality  ||| S:422 E:432 ||| NN
estimation  ||| S:432 E:443 ||| VBZ
resulting  ||| S:443 E:453 ||| VBG
from  ||| S:453 E:458 ||| IN
loss  ||| S:458 E:463 ||| NN
from  ||| S:463 E:468 ||| IN
follow-up ||| S:468 E:477 ||| NNP
,  ||| S:477 E:479 ||| ,
based  ||| S:479 E:485 ||| VBN
on  ||| S:485 E:488 ||| IN
double-sampling  ||| S:488 E:504 ||| JJ
methods  ||| S:504 E:512 ||| NNS
applied  ||| S:512 E:520 ||| VBN
to  ||| S:520 E:523 ||| TO
patient  ||| S:523 E:531 ||| JJ
outreach  ||| S:531 E:540 ||| NNS
( ||| S:540 E:541 ||| -LRB-
Kenya ||| S:541 E:546 ||| NNP
)  ||| S:546 E:548 ||| -RRB-
and  ||| S:548 E:552 ||| CC
linkage  ||| S:552 E:560 ||| NN
with  ||| S:560 E:565 ||| IN
vital  ||| S:565 E:571 ||| JJ
registries  ||| S:571 E:582 ||| NNS
( ||| S:582 E:583 ||| -LRB-
South  ||| S:583 E:589 ||| NNP
Africa ||| S:589 E:595 ||| NNP
) ||| S:595 E:596 ||| -RRB-
,  ||| S:596 E:598 ||| ,
and  ||| S:598 E:602 ||| CC
apply  ||| S:602 E:608 ||| VB
these  ||| S:608 E:614 ||| DT
to  ||| S:614 E:617 ||| TO
mortality  ||| S:617 E:627 ||| NN
estimates  ||| S:627 E:637 ||| NNS
in  ||| S:637 E:640 ||| IN
the  ||| S:640 E:644 ||| DT
other  ||| S:644 E:650 ||| JJ
three  ||| S:650 E:656 ||| CD
regions ||| S:656 E:663 ||| NNS
.  ||| S:663 E:665 ||| .
Age ||| S:665 E:668 ||| NN
,  ||| S:668 E:670 ||| ,
gender  ||| S:670 E:677 ||| NN
and  ||| S:677 E:681 ||| CC
CD4  ||| S:681 E:685 ||| CD
count  ||| S:685 E:691 ||| NN
at  ||| S:691 E:694 ||| IN
the  ||| S:694 E:698 ||| DT
initiation  ||| S:698 E:709 ||| NN
of  ||| S:709 E:712 ||| IN
therapy  ||| S:712 E:720 ||| NN
were  ||| S:720 E:725 ||| VBD
the  ||| S:725 E:729 ||| DT
factors  ||| S:729 E:737 ||| NNS
considered  ||| S:737 E:748 ||| VBN
as  ||| S:748 E:751 ||| IN
predictors  ||| S:751 E:762 ||| NN
of  ||| S:762 E:765 ||| IN
mortality  ||| S:765 E:775 ||| NN
at  ||| S:775 E:778 ||| IN
6 ||| S:778 E:779 ||| CD
,  ||| S:779 E:781 ||| ,
12 ||| S:781 E:783 ||| CD
,  ||| S:783 E:785 ||| ,
24  ||| S:785 E:788 ||| CD
and  ||| S:788 E:792 ||| CC
> ||| S:792 E:793 ||| CD
24  ||| S:793 E:796 ||| CD
months  ||| S:796 E:803 ||| NNS
after  ||| S:803 E:809 ||| IN
the  ||| S:809 E:813 ||| DT
start  ||| S:813 E:819 ||| NN
of  ||| S:819 E:822 ||| IN
treatment ||| S:822 E:831 ||| NN
.  ||| S:831 E:833 ||| .
Patient  ||| S:833 E:841 ||| JJ
mortality  ||| S:841 E:851 ||| NN
was  ||| S:851 E:855 ||| VBD
high  ||| S:855 E:860 ||| JJ
during  ||| S:860 E:867 ||| IN
the  ||| S:867 E:871 ||| DT
first  ||| S:871 E:877 ||| JJ
6  ||| S:877 E:879 ||| CD
months  ||| S:879 E:886 ||| NNS
after  ||| S:886 E:892 ||| IN
therapy  ||| S:892 E:900 ||| NN
for  ||| S:900 E:904 ||| IN
all  ||| S:904 E:908 ||| DT
patient  ||| S:908 E:916 ||| JJ
subgroups  ||| S:916 E:926 ||| NNS
and  ||| S:926 E:930 ||| CC
exceeded  ||| S:930 E:939 ||| VBD
40  ||| S:939 E:942 ||| CD
per  ||| S:942 E:946 ||| IN
100  ||| S:946 E:950 ||| CD
patient  ||| S:950 E:958 ||| NN
years  ||| S:958 E:964 ||| NNS
among  ||| S:964 E:970 ||| IN
patients  ||| S:970 E:979 ||| NNS
who  ||| S:979 E:983 ||| WP
started  ||| S:983 E:991 ||| VBD
treatment  ||| S:991 E:1001 ||| NN
at  ||| S:1001 E:1004 ||| IN
low  ||| S:1004 E:1008 ||| JJ
CD4  ||| S:1008 E:1012 ||| CD
count ||| S:1012 E:1017 ||| NN
.  ||| S:1017 E:1019 ||| .
This  ||| S:1019 E:1024 ||| DT
trend  ||| S:1024 E:1030 ||| NN
was  ||| S:1030 E:1034 ||| VBD
seen  ||| S:1034 E:1039 ||| VBN
regardless  ||| S:1039 E:1050 ||| RB
of  ||| S:1050 E:1053 ||| IN
region ||| S:1053 E:1059 ||| NN
,  ||| S:1059 E:1061 ||| ,
demographic  ||| S:1061 E:1073 ||| JJ
or  ||| S:1073 E:1076 ||| CC
disease-related  ||| S:1076 E:1092 ||| JJ
risk  ||| S:1092 E:1097 ||| NN
factor ||| S:1097 E:1103 ||| NN
.  ||| S:1103 E:1105 ||| .
Mortality  ||| S:1105 E:1115 ||| NN
was  ||| S:1115 E:1119 ||| VBD
under-reported  ||| S:1119 E:1134 ||| JJ
by  ||| S:1134 E:1137 ||| IN
up  ||| S:1137 E:1140 ||| RB
to  ||| S:1140 E:1143 ||| TO
or  ||| S:1143 E:1146 ||| CC
exceeding  ||| S:1146 E:1156 ||| VBG
100 ||| S:1156 E:1159 ||| CD
%  ||| S:1159 E:1161 ||| NN
when  ||| S:1161 E:1166 ||| WRB
comparing  ||| S:1166 E:1176 ||| JJ
estimates  ||| S:1176 E:1186 ||| NNS
obtained  ||| S:1186 E:1195 ||| VBN
from  ||| S:1195 E:1200 ||| IN
passive  ||| S:1200 E:1208 ||| JJ
monitoring  ||| S:1208 E:1219 ||| NN
of  ||| S:1219 E:1222 ||| IN
patient  ||| S:1222 E:1230 ||| JJ
vital  ||| S:1230 E:1236 ||| JJ
status ||| S:1236 E:1242 ||| NN
.  ||| S:1242 E:1244 ||| .
Despite  ||| S:1244 E:1252 ||| IN
advances  ||| S:1252 E:1261 ||| NNS
in  ||| S:1261 E:1264 ||| IN
antiretroviral  ||| S:1264 E:1279 ||| JJ
treatment  ||| S:1279 E:1289 ||| NN
coverage  ||| S:1289 E:1298 ||| NN
many  ||| S:1298 E:1303 ||| JJ
patients  ||| S:1303 E:1312 ||| NNS
start  ||| S:1312 E:1318 ||| VBP
treatment  ||| S:1318 E:1328 ||| NN
at  ||| S:1328 E:1331 ||| IN
very  ||| S:1331 E:1336 ||| RB
low  ||| S:1336 E:1340 ||| JJ
CD4  ||| S:1340 E:1344 ||| CD
counts  ||| S:1344 E:1351 ||| NNS
and  ||| S:1351 E:1355 ||| CC
experience  ||| S:1355 E:1366 ||| VB
significant  ||| S:1366 E:1378 ||| JJ
mortality  ||| S:1378 E:1388 ||| NN
during  ||| S:1388 E:1395 ||| IN
the  ||| S:1395 E:1399 ||| DT
first  ||| S:1399 E:1405 ||| JJ
6  ||| S:1405 E:1407 ||| CD
months  ||| S:1407 E:1414 ||| NNS
after  ||| S:1414 E:1420 ||| IN
treatment  ||| S:1420 E:1430 ||| NN
initiation ||| S:1430 E:1440 ||| NN
.  ||| S:1440 E:1442 ||| .
Active  ||| S:1442 E:1449 ||| JJ
patient  ||| S:1449 E:1457 ||| NN
tracing  ||| S:1457 E:1465 ||| NNS
and  ||| S:1465 E:1469 ||| CC
linkage  ||| S:1469 E:1477 ||| NN
with  ||| S:1477 E:1482 ||| IN
vital  ||| S:1482 E:1488 ||| JJ
registries  ||| S:1488 E:1499 ||| NNS
are  ||| S:1499 E:1503 ||| VBP
critical  ||| S:1503 E:1512 ||| JJ
in  ||| S:1512 E:1515 ||| IN
adjusting  ||| S:1515 E:1525 ||| VBG
estimates  ||| S:1525 E:1535 ||| NNS
of  ||| S:1535 E:1538 ||| IN
mortality ||| S:1538 E:1547 ||| NN
,  ||| S:1547 E:1549 ||| ,
particularly  ||| S:1549 E:1562 ||| RB
in  ||| S:1562 E:1565 ||| IN
low-  ||| S:1565 E:1570 ||| JJ
and  ||| S:1570 E:1574 ||| CC
middle-income  ||| S:1574 E:1588 ||| JJ
settings ||| S:1588 E:1596 ||| NNS
.  ||| S:1596 E:1598 ||| .
